

Marcus Ulrich Hentrich

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/297691/publications.pdf>

Version: 2024-02-01

68
papers

2,216
citations

236925

25
h-index

243625

44
g-index

74
all docs

74
docs citations

74
times ranked

2793
citing authors

#	ARTICLE	IF	CITATIONS
1	Serum Levels of MicroRNA-371a-3p (M371 Test) as a New Biomarker of Testicular Germ Cell Tumors: Results of a Prospective Multicentric Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1412-1423.	1.6	246
2	Impact of human herpesvirus-6 after haematopoietic stem cell transplantation. <i>British Journal of Haematology</i> , 2005, 128, 66-72.	2.5	144
3	Stage-Adapted Treatment of HIV-Associated Hodgkin Lymphoma: Results of a Prospective Multicenter Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 4117-4123.	1.6	111
4	Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1563-1574.	1.6	108
5	Antiviral prophylaxis in patients with solid tumours and haematological malignanciesâ€”update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2015, 94, 1441-1450.	1.8	98
6	Management of sepsis in neutropenic patients: 2014 updated guidelines from the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology (AGIHO). <i>Annals of Hematology</i> , 2014, 93, 1083-1095.	1.8	86
7	Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium. <i>Journal of Clinical Oncology</i> , 2021, 39, 1553-1562.	1.6	83
8	IgMA-enriched immunoglobulin in neutropenic patients with sepsis syndrome and septic shock: A randomized, controlled, multiple-center trial*. <i>Critical Care Medicine</i> , 2006, 34, 1319-1325.	0.9	77
9	Acquired immunodeficiency syndrome-related lymphoma. <i>Cancer</i> , 2006, 106, 1560-1568.	4.1	77
10	Should the standard dimethyl sulfoxide concentration be reduced? Results of a European Group for Blood and Marrow Transplantation prospective noninterventonal study on usage and side effects of dimethyl sulfoxide. <i>Transfusion</i> , 2014, 54, 2514-2522.	1.6	75
11	Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. <i>Lancet Respiratory Medicine</i> , 2021, 9, 863-872.	10.7	75
12	Dose-dense induction with sequential high-dose cytarabine and mitoxantone (S-HAM) and pegfilgrastim results in a high efficacy and a short duration of critical neutropenia in de novo acute myeloid leukemia: a pilot study of the AMLCG. <i>Blood</i> , 2009, 113, 3903-3910.	1.4	57
13	Poor outcome of HIV-infected patients with plasmablastic lymphoma. <i>Aids</i> , 2013, 27, 842-845.	2.2	57
14	Central venous catheterâ€”related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2021, 100, 239-259.	1.8	54
15	Survival of AIDS-related diffuse large B-cell lymphoma, Burkitt lymphoma, and plasmablastic lymphoma in the German HIV Lymphoma Cohort. <i>British Journal of Haematology</i> , 2015, 168, 806-810.	2.5	53
16	Management and outcome of bilateral testicular germ cell tumors: Twenty-five year experience in Munich. <i>Acta Oncologica</i> , 2005, 44, 529-536.	1.8	47
17	Treatment of invasive fungal diseases in cancer patientsâ€”Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). <i>Mycoses</i> , 2020, 63, 653-682.	4.0	42
18	Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients. <i>Leukemia and Lymphoma</i> , 2014, 55, 2341-2348.	1.3	34

#	ARTICLE	IF	CITATIONS
19	Prophylaxis, diagnosis and therapy of infections in patients undergoing high-dose chemotherapy and autologous haematopoietic stem cell transplantation. 2020 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO). <i>Annals of Hematology</i> , 2021, 100, 321-336.	1.8	34
20	Therapy of HIV-associated lymphoma – recommendations of the oncology working group of the German Study Group of Physicians in Private Practice Treating HIV-Infected Patients (DAGNÄ,,), in cooperation with the German AIDS Society (DAIG). <i>Annals of Hematology</i> , 2014, 93, 913-921.	1.8	33
21	Evidence-based management of COVID-19 in cancer patients: Guideline by the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). <i>European Journal of Cancer</i> , 2020, 140, 86-104.	2.8	33
22	Treatment of AIDS-related lymphomas. <i>Aids</i> , 2012, 26, 457-464.	2.2	29
23	Autotransplant with and without induction chemotherapy in older multiple myeloma patients: long-term outcome of a randomized trial. <i>Haematologica</i> , 2016, 101, 1398-1406.	3.5	28
24	Allogeneic transplantation in multiple myeloma: long-term follow-up and cytogenetic subgroup analysis. <i>Leukemia</i> , 2019, 33, 2710-2719.	7.2	28
25	Stem cell mobilization in HIV seropositive patients with lymphoma. <i>Haematologica</i> , 2013, 98, 1762-1768.	3.5	27
26	HIV-Associated Malignant Lymphoma. <i>Oncology Research and Treatment</i> , 2017, 40, 82-87.	1.2	27
27	Nivolumab in HIV-related non-small-cell lung cancer. <i>Annals of Oncology</i> , 2017, 28, 2890.	1.2	27
28	Incidence and risk factors for relapses in HIV-associated non-Hodgkin lymphoma as observed in the German HIV-related lymphoma cohort study. <i>Haematologica</i> , 2018, 103, 857-864.	3.5	27
29	AIDS-associated Burkitt or Burkitt-like lymphoma: Short intensive polychemotherapy is feasible and effective. <i>Leukemia and Lymphoma</i> , 2006, 47, 1872-1880.	1.3	25
30	Malignant lymphoma in the HIV-positive patient. <i>European Journal of Haematology</i> , 2018, 101, 119-126.	2.2	25
31	Everolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 717-723.	2.5	25
32	Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1062-1067.	1.3	23
33	Outcome of Men With Relapses After Adjuvant Bleomycin, Etoposide, and Cisplatin for Clinical Stage I Nonseminoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1322-1331.	1.6	23
34	Bortezomib in Combination with High-Dose Dexamethasone and Continuous Low-Dose Oral Cyclophosphamide for Relapsed Multiple Myeloma. <i>Blood</i> , 2005, 106, 2549-2549.	1.4	19
35	Fatal tumor lysis syndrome after irinotecan/5-FU/folinic acid/bevacizumab-containing therapy in a patient heavily pretreated for metastatic colon cancer. <i>Acta Oncologica</i> , 2008, 47, 155-156.	1.8	16
36	HIV-Associated Lung Cancer. <i>Oncology Research and Treatment</i> , 2017, 40, 88-92.	1.2	16

#	ARTICLE	IF	CITATIONS
37	Smoking cessation in long-term survivors of germ cell tumour. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 557-560.	2.5	15
38	Testing G-CSF responsiveness predicts the individual susceptibility to infection and consecutive treatment in recipients of high-dose chemotherapy. <i>Blood</i> , 2011, 117, 2121-2128.	1.4	15
39	Etoposide, Cisplatin, Bleomycin, And Cyclophosphamide (Ecbc) As First-Line Chemotherapy for Poor-Risk Non-Seminomatous Germ Cell Tumors. <i>Acta Oncologica</i> , 1993, 32, 541-546.	1.8	13
40	CD4+ and CD8+ T-cell kinetics in aviremic HIV-infected patients developing Hodgkin or non-Hodgkin lymphoma. <i>Aids</i> , 2016, 30, 753-760.	2.2	13
41	Characteristics and outcome of human immunodeficiency virus (HIV)-associated primary effusion lymphoma as observed in the German HIV-related lymphoma cohort study. <i>British Journal of Haematology</i> , 2021, 194, 642-646.	2.5	12
42	First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG). <i>Journal of Cancer Research and Clinical Oncology</i> , 2014, 140, 1211-20.	2.5	11
43	Autologous stem cell transplantation for HIV-associated lymphoma in the antiretroviral and rituximab era: a retrospective study by the EBMT Lymphoma Working Party. <i>Bone Marrow Transplantation</i> , 2019, 54, 1625-1631.	2.4	11
44	Characteristics and outcomes of patients with cancer and COVID-19: results from a cohort study. <i>Acta Oncologica</i> , 2021, 60, 24-27.	1.8	11
45	FDG PET scan (PET) positive residual lesions after chemotherapy (chemo) for metastatic seminoma: Results of an International Global Germ Cell Cancer Group (G3) registry.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4521-4521.	1.6	11
46	HIV-Associated Urogenital Malignancies. <i>Oncology Research and Treatment</i> , 2017, 40, 106-112.	1.2	10
47	Intermediate prognosis in metastatic germ cell tumours—outcome and prognostic factors. <i>European Journal of Cancer</i> , 2018, 94, 16-25.	2.8	10
48	The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3). <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 809.e19-809.e25.	1.6	10
49	Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 449-455.	2.5	10
50	Central venous catheter-related bloodstream infections in patients with hematological malignancies: Comparison of data from a clinical registry and a randomized controlled trial. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 1-3.	1.8	9
51	Tissue Levels of Reduced Folates in Patients with Colorectal Carcinoma After Infusion of Folinic Acid at Various Dose Levels. <i>Clinical Cancer Research</i> , 2008, 14, 7930-7934.	7.0	8
52	Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis. <i>Blood Advances</i> , 2019, 3, 2696-2699.	5.2	8
53	Improved outcomes in metastatic germ cell cancer: results from a large cohort study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 533-538.	2.5	8
54	Early Autologous Stem Cell Transplantation (SCT) in Genetically Poor-Risk Chronic Lymphocytic Leukemia Is Feasible and Effective: Results from a Prospective Multicenter Study (GCLLSG CLL3) Tj ETQq0 0 0 rgBT {Qverlock&0 Tf 50 5		

#	ARTICLE	IF	CITATIONS
55	Impact of neutropenia on central venous catheter-related bloodstream infections in patients with hematological malignancies at the time of central venous catheter insertion: A matched-pair analysis. <i>Infection Control and Hospital Epidemiology</i> , 2019, 40, 1204-1206.	1.8	7
56	Severe motor aphasia after reinfusion of cryopreserved autologous stem cells after myeloablative conditioning. <i>Transfusion</i> , 2016, 56, 2615-2617.	1.6	4
57	The prognostic significance of lactate dehydrogenase levels in seminoma patients with advanced disease: an analysis by the Global Germ Cell Tumor Collaborative Group (G3). <i>World Journal of Urology</i> , 2021, 39, 3407-3414.	2.2	4
58	Prospective Randomized Trial of Len/Dex Induction Followed by Tandem MEL140 with Autologous Blood Stem Cell Transplantation and Len Maintenance Versus Continued Therapy with Len/Dex in Myeloma Patients Age 60-75 Years: Protocol-Defined Safety Analysis After 100 Patients. <i>Blood</i> , 2012, 120, 2012-2012.	1.4	4
59	Single-course bleomycin, etoposide, and cisplatin (1xBEP) as adjuvant treatment in testicular nonseminoma clinical stage 1: outcome, safety, and risk factors for relapse in a population-based study. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210868.	3.2	4
60	Autologous Stem Cell Transplantation (ASCT) in HIV Associated Lymphoma (HIV-Ly) Patients: The EBMT Lymphoma Working Party (EBMT-LWP) Experience.. <i>Blood</i> , 2006, 108, 3042-3042.	1.4	3
61	Autologous Stem Cell Transplantation (autoSCT) for HIV-Associated Lymphoma in the Era of Combination Antiretroviral Therapy (cART): A Retrospective Analysis of the EBMT Lymphoma Working Party. <i>Blood</i> , 2016, 128, 2257-2257.	1.4	3
62	Outcomes of men with HIV and germ cell cancer: Results from an international collaborative study. <i>Cancer</i> , 2022, 128, 260-268.	4.1	1
63	Lenalidomide with Low-Dose Dexamethasone (Rd) Continuously Versus Rd Induction, Tandem MEL140 with Autologous Transplantation and Lenalidomide Maintenance: Planned Interim Analysis of a Prospective Randomized Trial in Patients 60-75 Years of Age with Multiple Myeloma. <i>Blood</i> , 2014, 124, 3969-3969.	1.4	1
64	Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, 510-510.	1.6	1
65	Overweight or obesity are not risk factors for central venous catheter-related bloodstream infections in patients with hematological malignancies. <i>Infection Control and Hospital Epidemiology</i> , 2021, , 1-3.	1.8	1
66	Efficacy and safety of gemcitabine, oxaliplatin and paclitaxel (GOP) in cisplatin-refractory germ cell tumors in routine care: Registry data from an outcomes research project.. <i>Journal of Clinical Oncology</i> , 2015, 33, e15570-e15570.	1.6	0
67	Intermediate prognosis in metastatic germ cell tumors (IPGCT): Outcome and prognostic factors.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4560-4560.	1.6	0
68	Outcome of men with HIV-associated germ cell cancer: Results from an international collaborative study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5053-5053.	1.6	0